<?xml version="1.0" encoding="UTF-8"?>
<p>In the first-ever study among severe COVID-19 patients, which was not designed as a properly controlled trial, it showed possible efficacy in about two-thirds of severe coronavirus patients. The study reported that the death rate of those on respirators decreased from about 50% to 15% [
 <xref rid="R34" ref-type="bibr">34</xref>]. Because of this, Remdesivir should be closely monitored. However, it should be reiterated that the studies conducted on medicines against COVID-19 so far have not adhered to the usual standards. They have been conducted without a control group and we will require much more extensive and better-designed research to properly understand the effectiveness of Remdesivir and other medicines. But in light of all current insights, Remdesivir, with the knowledge of a lower “death rate” in the community, is still the best news we currently have on this front.
</p>
